OPTF01
/ Optieum Biotechnologies
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 08, 2025
Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
(PRNewswire)
- "Cellipont Bioservices...and Optieum Biotechnologies (Optieum)...announced a partnership for cGMP manufacturing of OPTF01, Optieum's novel CAR-T therapy for glioblastoma treatment, a product derived from their proprietary Eumbody System....Under this collaboration, Cellipont Bioservices will provide the technology transfer, process development, and cGMP manufacturing of Optieum's novel OPTF01 CAR-T product."
Commercial • Glioblastoma
May 05, 2025
Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
(PRNewswire)
- "Genezen...and Optieum Biotechnologies, Inc...announced a partnership for cGMP manufacturing of the lentiviral vector (LVV) construct used in the production of OPTF01, a novel CAR-T therapy for glioblastoma treatment....Under this collaboration, Genezen will provide the technology transfer, process development, and cGMP manufacturing of the LVV construct used in the onward production of the OPTF01 CAR-T product."
Commercial • Glioblastoma
1 to 2
Of
2
Go to page
1